| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DCN |
| Uniprot No | P07585 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-359aa |
| 氨基酸序列 | DEASGIGPEV PDDRDFEPSL GPVCPFRCQC HLRVVQCSDL GLDKVPKDLP PDTTLLDLQN NKITEIKDGD FKNLKNLHAL ILVNNKISKV SPGAFTPLVK LERLYLSKNQ LKELPEKMPK TLQELRAHEN EITKVRKVTF NGLNQMIVIE LGTNPLKSSG IENGAFQGMK KLSYIRIADT NITSIPQGLP PSLTELHLDG NKISRVDAAS LKGLNNLAKL GLSFNSISAV DNGSLANTPH LRELHLDNNK LTRVPGGLAE HKYIQVVYLH NNNISVVGSS DFCPPGHNTK KASYSGVSLF SNPVQYWEIQ PSTFRCVYVR SAIQLGNYK |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DCN(Decorin，核心蛋白聚糖)重组蛋白研究的参考文献示例(注：文献标题和作者为模拟示例，实际需通过学术数据库查询)：
---
1. **"Recombinant human decorin: production and therapeutic potential in fibrotic diseases"**
- 作者：Smith A, et al.
- 摘要：研究报道了利用哺乳动物细胞表达系统高效生产重组人Decorin的方法，并证明其通过抑制TGF-β信号通路显著减轻肺纤维化模型中的胶原沉积。
2. **"Structural and functional characterization of decorin core protein expressed in E. coli"**
- 作者：Wang L, et al.
- 摘要：通过大肠杆菌表达系统获得非糖基化Decorin核心蛋白，解析其三维结构，验证其与胶原纤维结合的能力及在调控细胞外基质重塑中的作用。
3. **"Decorin-based nanocarriers for targeted cancer therapy"**
- 作者：Chen X, et al.
- 摘要：开发了一种基于重组Decorin的纳米递送系统，利用Decorin与肿瘤细胞表面受体的特异性结合，增强化疗药物的靶向递送并抑制肿瘤转移。
4. **"Decorin recombinant protein attenuates myocardial fibrosis via modulating MMP-9/TIMP-1 balance"**
- 作者：Zhang Y, et al.
- 摘要：在心肌梗死模型中，重组Decorin通过调节基质金属蛋白酶(MMPs)及其抑制剂的平衡，减少心肌纤维化并改善心脏功能。
---
建议通过PubMed、Web of Science或Google Scholar搜索关键词“recombinant decorin protein”获取真实文献。
**Background of Recombinant Decorin (DCN) Protein**
Decorin (DCN), a small leucine-rich proteoglycan, is a key component of the extracellular matrix (ECM) involved in regulating tissue organization, collagen fibrillogenesis, and cellular signaling. It consists of a core protein (∼40 kDa) and a single glycosaminoglycan (GAG) chain, typically chondroitin or dermatan sulfate. Decorin interacts with collagen fibrils to control their assembly and stability, while its GAG chain binds growth factors like TGF-β, modulating their bioavailability and activity. These interactions underlie decorin’s roles in wound healing, fibrosis suppression, and tumor suppression.
Recombinant decorin protein is produced via genetic engineering in host systems (e.g., *E. coli*, mammalian cells) to study its therapeutic potential. Unlike native decorin, recombinant versions often lack GAG chains unless expressed in mammalian systems, which complicates post-translational modifications. However, prokaryotic systems offer cost-effective, high-yield production of the core protein, retaining bioactivity for certain applications.
Research highlights decorin’s ability to neutralize TGF-β, a driver of fibrosis and cancer progression, making recombinant DCN a candidate for treating fibrotic diseases (e.g., liver fibrosis, pulmonary fibrosis) and cancers. It also inhibits angiogenesis and promotes apoptosis in tumor cells by targeting receptor tyrosine kinases (e.g., EGFR, Met). Additionally, decorin shows promise in regenerative medicine by enhancing ECM repair in damaged tissues.
Challenges remain in optimizing recombinant decorin’s structure-function fidelity and delivery methods. Advances in glycoengineering and hybrid expression systems aim to improve its therapeutic efficacy. Overall, recombinant decorin represents a multifaceted biologic bridging ECM biology and clinical innovation.
×
